Ariad Pharmaceuticals Inc fka ARIA

[wrkingcapital]

Fixated on Sarcoma Trial
Was just reviewing median survival figures in patients with metestatic sarcoma and noted that 90% do not survive beyond one year....I am wondering if the longer delay between interim 2 and 3 may relate to the secondary end point of overall survival built into the study. I know that this was important to the FDA as far as trial design but less so to ARIAD. Anyway I was thinking that this is what we may be delayed by...evidence of delayed progression is likely to be found out earlier than the secondary end point of overall survival. it was important to the FDA and obviously the SARCOMA community so perhaps that explains the longer interval for results that we are currently experiencing. Any thoughts?